79 recruiting. 79 Phase 2, 17 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 79 | Recruiting 79 |
| Phase 1 | 17 | Recruiting 17 |
| Phase 3 | 6 | Recruiting 6 |
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease RO7568282, Placebo - Alzheimer's Disease | Phase 2 | Recruiting | Hoffmann-La Roche | 450 | 2026-11-15 | 2026-11-06 |
| Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin Psilocybin, Cognitive Training - Alzheimer's Disease | Phase 2 | Recruiting | National Institute on Aging (NIA) | 200 | 2026-11-15 | 2026-11-10 |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-10-01 | 2026-11-05 |
| Flutemetamol F 18 Injection Formulation Comparison GE-287, Vizamyl - Cognitive Dysfunction | Phase 2 | Recruiting | GE Healthcare | 20 | 2026-09-30 | 2026-11-05 |
| Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease Obicetrapib 10 mg, Matching placebo tablets - Preclinical Alzheimer's Disease | Phase 2 | Recruiting | NewAmsterdam Pharma | 400 | 2026-09-01 | 2026-09-28 |
| Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease IL-2 (Aldesleukin), Semaglutide Plus IL-2, Placebo - Alzheimer Dementia (AD) | Phase 1 / Phase 2 | Recruiting | The Methodist Hospital Research Institute | 30 | 2026-09-01 | 2026-11-06 |
| N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease Nicotinamide Riboside (NR), Palacebo - Alzheimer Disease (AD) | Phase 2 | Recruiting | Haukeland University Hospital | 270 | 2026-08-26 | 2026-08-20 |
| The Progressive Supranuclear Palsy Clinical Trial Platform AADvac1, LM11A-31 - Progressive Supranuclear Palsy(PSP) | Phase 2 | Recruiting | Adam Boxer | 440 | 2026-07-29 | 2026-11-10 |
| A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease SAR448851, Placebo - Dementia, Alzheimer's Type, Alzheimer's Disease | Phase 2 | Recruiting | Sanofi | 160 | 2026-07-28 | 2026-11-06 |
| Low-Dose Radiotherapy for Alzheimer's Disease Low Dose Radiation Therapy - Alzheimer Dementia, Dementia | Phase 1 / Phase 2 | Recruiting | Evan Thomas | 50 | 2026-07-15 | 2026-07-09 |
| A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease Donanemab, RG6289, Donanemab placebo - Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease | Phase 2 / Phase 3 | Recruiting | Banner Health | 240 | 2026-07-08 | 2026-09-02 |
| Alzheimer's Tau Platform: Master Protocol AADvac1, Tau2 - Preclinical Alzheimer's Disease, Alzheimer Disease | Phase 2 | Recruiting | Paul S. Aisen | 900 | 2026-07-06 | 2026-10-26 |
| A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) Donanemab, Placebo - Cognitive Dysfunction, Lewy Body Disease | Phase 2 | Recruiting | Eli Lilly and Company | 350 | 2026-05-20 | 2026-11-04 |
| A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease ABBV-1758, Placebo for ABBV-1758 - Alzheimer's Disease | Phase 1 / Phase 2 | Recruiting | AbbVie | 210 | 2026-05-15 | 2026-09-18 |
| Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease. human Mesenchymal Stem Cells - Mild Cognitive Impairment, Early Alzheimer's Disease | Phase 2 | Recruiting | Bernard (Barry) Baumel | 10 | 2026-05-15 | 2026-05-28 |
| Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers HT-4253, Placebo - Alzheimers Disease | Phase 2 | Recruiting | Halia Therapeutics, Inc. | 112 | 2026-05-12 | 2026-08-05 |
| Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease CellREADY® drug product IV dose of 50 millions, CellREADY® drug product IV dose of 100 millions, cerebral RMI - Alzheimer Disease | Phase 1 / Phase 2 | Recruiting | University Hospital, Toulouse | 9 | 2026-05-07 | 2026-06-23 |
| Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease Leronlimab (700mg) - Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Alzheimer's Disease | Phase 2 | Recruiting | Weill Medical College of Cornell University | 20 | 2026-04-30 | 2026-05-22 |
| Biomarker-based Trial of NPC-1 for Alzheimer's Pathology natural product combination-1 (NPC1) - Alzheimer Disease, Mild Cognitive Impairment (MCI) | Phase 2 | Recruiting | Massachusetts General Hospital | 40 | 2026-04-01 | 2026-10-13 |
| Stem Cell Therapy for Early Alzheimer's Disease adMSC - Cognitive Dysfunction | Phase 1 / Phase 2 | Recruiting | Paul E Schulz | 12 | 2026-03-11 | 2026-04-20 |
Showing 20 of 79. Sign in to see all of them.
Alzheimer Disease (76) · Cognitive Dysfunction (24) · Dementia (21) · Brain Diseases (5) · Nervous System Diseases (5) · Central Nervous System Diseases (4) · Neurocognitive Disorders (4) · Supranuclear Palsy, Progressive (4) · Down Syndrome (3) · Frontotemporal Dementia (3) · Mental Disorders (3) · Neurodegenerative Diseases (3) · Parkinson Disease (3) · Psychomotor Agitation (3) · Sleep Initiation and Maintenance Disorders (3)
Neurodegenerative Diseases (76) · Central Nervous System Diseases (75) · Brain Diseases (74) · Nervous System Diseases (74) · Mental Disorders (73) · Neurocognitive Disorders (72) · Dementia (55) · Cognition Disorders (23) · Pathological Conditions, Signs and Symptoms (21) · Neurologic Manifestations (16) · Signs and Symptoms (14) · Neurobehavioral Manifestations (11) · Basal Ganglia Diseases (7) · Metabolic Diseases (6)
AADvac1 (2) · Magnetic Resonance Spectroscopy (2) · Positron-Emission Tomography (2) · daridorexant (2) · donanemab (2) · flutemetamol (2) · nicotinamide-beta-riboside (2) · semaglutide (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific) (1) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · Blood Specimen Collection (1) · Bumetanide (1) · CORT 108297 (1) · Cannabidiol (1)
Sunnybrook Health Sciences Centre (3) · Bernard (Barry) Baumel (2) · Brigham and Women's Hospital (2) · Haukeland University Hospital (2) · Massachusetts General Hospital (2) · Rutgers, The State University of New Jersey (2) · University Hospital, Toulouse (2) · University of Colorado, Denver (2) · University of Minnesota (2) · Washington University School of Medicine (2) · AC Immune SA (1) · AbbVie (1) · Adam Boxer (1) · Akiva Mintz (1) · Amydis Inc. (1)
United States (56) · Canada (11) · Australia (7) · Spain (7) · Argentina (6) · China (6) · France (6) · South Korea (6) · United Kingdom (6) · Germany (4) · Italy (4) · Norway (4) · Taiwan (4) · Colombia (3) · Netherlands (3)
Adam Boxer, MD, PhD (2) · Brendan Lucey, MD (2) · Eric M McDade, DO (2) · Alexander C Conley, Ph.D. (1) · Ana Trisini Lipsanopoulos, BS (1) · Anne-Marie Wills, MD (1) · Bernard Baumel, MD (1) · Bernard S. Baumel, MD (1) · Boris Decourt, PhD (1) · Charalampos Tzoulis, MD, PhD (1) · Ching-Kuan Liu, Dr. (1) · Ciprian Catana, MD, PhD (1)
PMID 33778150, PMID 36048943, PMID 36454969, PMID 37310119, PMID 38630948, PMID 40065917, PMID 40640892, PMID 40924149
2023 (2), 2025 (2), U01AG059798 (2), K23AG097987 (1), P30AG086401 (1), R01AG055425 (1), R01AG063888 (1), R01AG071151 (1), R01AG073212 (1), R01AG078457 (1), R01AG080551 (1), R01AG085029 (1), R01AG086363 (1), R01HL109448 (1)